Literature DB >> 20686004

The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations.

Daniel Bolliger1, Fania Szlam, Marc Azran, Kaoru Koyama, Jerrold H Levy, Ross J Molinaro, Kenichi A Tanaka.   

Abstract

BACKGROUND: Protamine sulfate is the antidote for heparin, but in excess it exerts weak anticoagulation.
METHODS: We evaluated the effects of increasing protamine concentrations (0 to 24 microg/mL) on prothrombin time and diluted Russell's viper venom time measurements on thrombin generation in platelet-poor and platelet-rich plasma after activation by tissue factor or actin, and on thromboelastometry in platelet-poor plasma and whole blood from 6 healthy volunteers. The reversibility of excess protamine (24 microg/mL) by recombinant factor VIIa or factor VIII/von Willebrand factor concentrate was also tested.
RESULTS: Protamine prolonged prothrombin time and Russell's viper venom time, concentration dependently. Protamine also increased lag time and decreased peak of thrombin generation in platelet-poor plasma after tissue factor and actin activation. In platelet-rich plasma with platelets at 50 to 200 x 10(3)/microL, protamine (24 microg/mL) prolonged the lag time, but had no effect on peak thrombin generation. The addition of factor VIII/von Willebrand factor (1.5-3.0 U/mL) to platelet-poor plasma with protamine (24 microg/mL) decreased lag time and increased peak thrombin generation with actin activation. A therapeutic concentration of recombinant factor VIIa (60 nM) only affected the lag time of thrombin generation triggered with actin. In agreement, protamine increased coagulation time evaluated by thromboelastometry significantly more in platelet-poor plasma than in whole blood.
CONCLUSIONS: We demonstrated that protamine affects the propagation of thrombin generation, which is partially reversed by platelets or increased factor VIII/von Willebrand factor concentrations. The present data suggest that excess protamine might potentially increase bleeding in the case of severe thrombocytopenia or low factor VIII.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686004     DOI: 10.1213/ANE.0b013e3181e9ed15

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

1.  [Hereditary heterozygous factor VII deficiency in patients undergoing surgery : Clinical relevance].

Authors:  D Woehrle; M Martinez; D Bolliger
Journal:  Anaesthesist       Date:  2016-09-01       Impact factor: 1.041

2.  [Application of standardized venous thromboembolism prevention program in burn patients].

Authors:  Yanqiong Wang; Jianqiong Huang; Xuewen Xu; Junjie Chen; Zhihui Wu; Jiali Gao; Jing Tang; Min Hu; Xia Yu
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-06-15

3.  Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation.

Authors:  S A Andrade; L C Carrijo-Carvalho; L A M Peceguini; L Wlian; A C Sato; C Luchiari; E D Silva; F H A Maffei; A M Chudzinski-Tavassi
Journal:  Braz J Med Biol Res       Date:  2012-06-28       Impact factor: 2.590

4.  Inpatient hemodialysis without anticoagulation in adults.

Authors:  Sheena Sahota; Roger Rodby
Journal:  Clin Kidney J       Date:  2014-10-30

5.  The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents.

Authors:  Joanna Miklosz; Bartlomiej Kalaska; Kamil Kaminski; Malgorzata Rusak; Krzysztof Szczubialka; Maria Nowakowska; Dariusz Pawlak; Andrzej Mogielnicki
Journal:  Mar Drugs       Date:  2019-09-17       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.